| Bioactivity | Retagliptin (SP2086) is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. Retagliptin can be used for type 2 diabetes mellitus (T2DM) research[1]. | ||||||||||||
| Invitro | Retagliptin is a class of compound used for research of type 2 diabetes. Retagliptin inhibits the degradation of GLP-1, thus amplifying the incretin effect[1]. | ||||||||||||
| Name | Retagliptin | ||||||||||||
| CAS | 1174122-54-3 | ||||||||||||
| Formula | C19H18F6N4O3 | ||||||||||||
| Molar Mass | 464.36 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Avivit Cahn, et al. An update on DPP-4 inhibitors in the management of type 2 diabetes. Expert Opin Emerg Drugs. 2016 Dec;21(4):409-419. |
Retagliptin
CAS: 1174122-54-3 F: C19H18F6N4O3 W: 464.36
Retagliptin (SP2086) is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. Retagliptin
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.